Market News & Trends
Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial
Evelo Biosciences, Inc. recently announced the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination…
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial
Dicerna Pharmaceuticals, Inc recently announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the company’s investigational GalXCTM-based therapy…
Seelos Therapeutics Announces Successful Completion of Merger With Apricus Biosciences
Seelos Therapeutics, Inc. recently announced the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics,…
Basilea Announces Collaboration With Roche to Study Derazantinib & Atezolizumab
Basilea Pharmaceutica Ltd. recently announced it entered into a collaboration with Roche to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab…
Proteon Therapeutics Announces Publication of Results From Phase 3 Clinical Trial
Proteon Therapeutics Inc. recently announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase.…
Dipharma Announces FDA Acceptance of ANDA of Generic
Dipharma S.A. recently announced that the US Food and Drug Administration (FDA) accepted its nitisinone abbreviated new drug application (ANDA) for review. Nitisinone is a…
Attune Pharmaceuticals Announces $23-Million Financing
Attune Pharmaceuticals, Inc. recently announced the completion of a $23 million Series B financing. Venrock Healthcare Partners led the financing joined by new investor LifeSci…
Gerresheimer Expands to Include Irradiation of Plastic Dropper Bottles
Gerresheimer used this year's Pharmapack held in Paris, Porte de Versailles, as a platform to unveil its latest ophthalmology and rhinology services. The company has…
Orion Biotechnology Reports Positive Results for Preclinical Study
Orion Biotechnology Canada Ltd. recently announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c…
Menlo Therapeutics Granted Breakthrough Therapy Designation
Menlo Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for serlopitant for the treatment of pruritus associated with prurigo nodularis (PN).…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….